Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Scilex Holding Company (SCLXW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: SCLXW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -53.83% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.14 | 52 Weeks Range 0.04 - 0.52 | Updated Date 06/14/2025 |
52 Weeks Range 0.04 - 0.52 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -146.93% | Operating Margin (TTM) -557.51% |
Management Effectiveness
Return on Assets (TTM) -69.26% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 4990167 |
Shares Outstanding - | Shares Floating 4990167 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Scilex Holding Company
Company Overview
History and Background
Scilex Holding Company is a biopharmaceutical company focused on acquiring, developing, and commercializing non-opioid therapies for patients suffering with acute and chronic pain. The company was founded with the goal of providing innovative and effective pain management solutions.
Core Business Areas
- Non-Opioid Pain Management: Development and commercialization of non-opioid pain relief products, focusing on novel formulations and delivery systems.
Leadership and Structure
Dr. Henry Ji serves as the Chairman and CEO. The company has a management team with expertise in pharmaceutical development, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- ZYDSO (diclofenac sodium topical system) 1.3%: A non-opioid topical pain reliever for acute pain. Market share data is not readily and publicly available. Competitors include other topical NSAIDs and pain relievers, and therapies (both opioid and non-opioid).
- Gloperba: A liquid oral colchicine for the treatment of gout flares. Market share data is not readily and publicly available. Competitors include other colchicine products and therapies for gout (both opioid and non-opioid).
- SEMDEXAu2122: Is a Phase 3, investigational, novel, non-opioid product candidate under development for the treatment of lumbosacral radicular pain (sciatica). Has not yet had any revenue.
Market Dynamics
Industry Overview
The pain management market is experiencing significant growth, driven by the aging population, increasing prevalence of chronic conditions, and growing demand for non-opioid alternatives due to the opioid crisis.
Positioning
Scilex Holding Company is positioned as a player in the non-opioid pain management space, aiming to provide safer and more effective treatment options. The company differentiate through novel formulations and delivery systems to improve patient outcomes.
Total Addressable Market (TAM)
The TAM for pain management is substantial, estimated to be in the billions of dollars annually. Scilex is positioned to capture a segment of this market by offering non-opioid alternatives.
Upturn SWOT Analysis
Strengths
- Focus on non-opioid pain management
- Novel drug delivery technologies
- Experienced management team
- Proprietary products
Weaknesses
- Limited product portfolio
- Reliance on key products
- High R&D expenses
- Currently involved in bankruptcy proceeding related to its parent company
Opportunities
- Expansion of product portfolio
- Partnerships and collaborations
- Growing demand for non-opioid pain relievers
- Geographic expansion
Threats
- Competition from larger pharmaceutical companies
- Regulatory challenges
- Patent expiration
- Changes in healthcare policies
Competitors and Market Share
Key Competitors
- TEVA
- Endo
- Mallinckrodt
Competitive Landscape
Scilex faces competition from established pharmaceutical companies with greater resources. Its competitive advantage lies in its focus on non-opioid therapies and innovative drug delivery systems.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is influenced by acquisitions and is not presented in a straightforward format.
Future Projections: Future growth is contingent on the successful development and commercialization of new products, particularly SEMDEXAu2122.
Recent Initiatives: Focus on advancing SEMDEXAu2122 through clinical trials and expanding commercial reach for existing products.
Summary
Scilex Holding Company is a biopharmaceutical company focused on the non-opioid pain management market. The company has proprietary products and is developing novel therapies, but it faces competition from larger pharmaceutical companies. Securing additional financing may be critical and will require careful monitoring. The future growth depends on the successful development and commercialization of its pipeline.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Market research reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Scilex Holding Company
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2021-03-08 | President, CEO & Director Mr. Jaisim Shah | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 111 | Website https://www.scilexholding.com |
Full time employees 111 | Website https://www.scilexholding.com | ||
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; and Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA. Scilex Holding Company is headquartered in Palo Alto, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.